Max Hodak, cofounder and former president of Neuralink, is now pursuing an even more ambitious vision with his new company Science Corporation (science.xyz). In a TechCrunch feature, Hodak outlines plans for biohybrid brain–computer interfaces (BCIs) that use living neurons instead of metal electrodes, alongside medical implants that restore lost vision.

Science is a clinical-stage neurotechnology company focused on treating severe neurological and retinal diseases while also exploring long-term questions about consciousness and “substrate-independent minds.”

• From Neuralink to Science: Hodak left Neuralink in 2021 and founded Science to take a different technical path toward BCIs, combining biology, optics, and semiconductor manufacturing.
• PRIMA retinal implant: The company’s flagship PRIMA device is a tiny wireless retinal prosthesis designed to restore central vision in patients with late-stage age-related macular degeneration and related diseases.
• Biohybrid interfaces: Science is developing biohybrid BCIs that embed living neurons inside devices which then interface with the brain, aiming to reduce scarring and enable higher-bandwidth, longer-lasting connections than traditional metal electrodes.
• Wild long-term vision: Hodak speculates that once we understand how billions of neurons bind into a unified conscious experience, future BCIs could allow multiple brains and machines to share a single extended mind, effectively “redrawing the border around a brain.”
• Mission: In the near term, Science focuses on restoring vision, cognition, and mobility for patients with no good options today, while using those clinical systems as stepping stones toward deeper understanding and engineering of the brain.

Why it matters: Science Corp sits at the frontier of both medicine and speculative neurotechnology. If its biohybrid interfaces and retinal implants succeed, they could not only restore crucial functions for patients, but also pave the way for radically new forms of human–machine and brain-to-brain communication in the decades ahead.